Hair Cycle Modulation To Promote Human Wound Healing

Sponsor
University of Hull (Other)
Overall Status
Suspended
CT.gov ID
NCT04753060
Collaborator
National Health Service, United Kingdom (Other)
11
1
2
29.2
0.4

Study Details

Study Description

Brief Summary

Chronic wounds represent a huge burden to both patients and the National Health Service (NHS), with over 200,000 sufferers in the UK alone. Based on current conservative estimates the NHS spends £2.3 - £3.1 billion pounds every year treating these patients.

This study aims to reduce this shared burden, preliminary data from our research group using animal models has demonstrated variable ability of hair follicles to heal wounds based upon their stage within their growth cycle. This currently proposed study therefore aims to perform a simple novel intervention on patients prior to their elective surgery in an effort to replicate the substantial healing abilities noted in the animal models.

Under normal circumstances, a patient's operative site is shaved prior to the surgery for hygiene and visual simplicity. The aim of this study is to wax 50% of the patient's operative site prior to their surgery, the other half will be shaved on the day of surgery as per normal surgical protocol. Based on known data this waxing technique will cycle the hair follicles into their growth phase at the time of surgery. The growth phase of hair follicles corresponds with an increased ability to heal due to recruitment of a patients own stem cells. This study therefore aims to take advantage of the patient's own stem cell population. The 50% waxing and 50% shaving method upon each patients donor site allows us to directly compare the influence of these two methods directly on a patient-by-patient basis.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Waxing
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
11 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Hair Cycle Modulation To Promote Human Wound Healing
Actual Study Start Date :
Jul 26, 2019
Actual Primary Completion Date :
Feb 21, 2020
Anticipated Study Completion Date :
Dec 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Waxing

Waxing of patients donor site who are undergoing a skingraft procedure, prior to surgery taking place.

Procedure: Waxing
Donor sites of patients skin grafts are waxed prior to surgery for donor harvesting.

No Intervention: Standard care

Standard wound preparation

Outcome Measures

Primary Outcome Measures

  1. Photograph Assessment [7 days post-surgery]

    Digital assessment of healing outcome from clinical wound photographs using novel scale (1-10). Higher score is representative of a better outcome.

  2. Photograph Assessment [14 days post-surgery]

    Digital assessment of healing outcome from clinical wound photographs using novel scale (1-10). Higher score is representative of a better outcome.

  3. Photograph Assessment [3 months post-surgery]

    Digital assessment of healing outcome from clinical wound photographs using novel scale (1-10). Higher score is representative of a better outcome.

Secondary Outcome Measures

  1. Post Operative Infection incidence [7 days post surgery]

    Clinical assessment reports a presence or absence of infection

  2. Post Operative Infection incidence [14 days post surgery]

    Clinical assessment reports a presence or absence of infection

  3. Post Operative Infection incidence [3 months post surgery]

    Clinical assessment reports a presence or absence of infection

  4. Changes To Patient Microbiome (Next-Generation Sequencing) [0, 7, 14 days and 3 months.]

    Changes to skin microbiome as compared to day 0 using next-generation sequencing.

  5. Histological Wound Healing Score [Day 0]

    H&E stained histological sections will be used to quantify healing using a study-specific scale (1-10). Higher score is representative of an improved outcome.

  6. Histological Wound Healing Score [7 days post surgery]

    H&E stained histological sections will be used to quantify healing using a study-specific scale (1-10). Higher score is representative of an improved outcome.

  7. Histological Wound Healing Score [14 days post surgery]

    H&E stained histological sections will be used to quantify healing using a study-specific scale (1-10). Higher score is representative of an improved outcome.

  8. Histological Wound Healing Score [3 months post surgery]

    H&E stained histological sections will be used to quantify healing using a study-specific scale (1-10). Higher score is representative of an improved outcome.

  9. Identification of Hair Cycle State via Histology [Day 0]

    Tissue biopsies will be analysed histologically to identify the presence of anagen and telogen hair follicles.

  10. Identification of Hair Cycle State via Histology [7 days post surgery]

    Tissue biopsies will be analysed histologically to identify the presence of anagen and telogen hair follicles.

  11. Identification of Hair Cycle State via Histology [14 days post surgery]

    Tissue biopsies will be analysed histologically to identify the presence of anagen and telogen hair follicles.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient is undergoing skin graft surgery

  • Patient is 18 years of age or older.

  • Written and informed consent provided.

Exclusion Criteria:
  • Participants that have been enrolled in a clinical trial within the last 3 months that would affect their ability to heal or influence hair cycle.

  • Specific hair-linked diseases, e.g. alopecia areata. (Not including androgenetic alopecia)

  • Lack of capacity to consent

  • Lymphedema

  • Malnutrition

  • Collagen disorders

  • Patients requiring grafts smaller than 5cm x 5cm

  • Patients requiring grafts wider than 10cm

  • Immunomodulation drugs

  • Patients will be excluded mid study if they develop an infection that prevents biopsy retrieval

Contacts and Locations

Locations

Site City State Country Postal Code
1 Castle Hill Hospital Hull East Yorkshire United Kingdom HU16 5JQ

Sponsors and Collaborators

  • University of Hull
  • National Health Service, United Kingdom

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Matthew Hardman, Chief Investigator, University of Hull
ClinicalTrials.gov Identifier:
NCT04753060
Other Study ID Numbers:
  • RS105
First Posted:
Feb 12, 2021
Last Update Posted:
Feb 12, 2021
Last Verified:
Feb 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Matthew Hardman, Chief Investigator, University of Hull
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 12, 2021